{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T07:02:02Z","timestamp":1769583722556,"version":"3.49.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.canlet.2021.11.003","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T22:29:15Z","timestamp":1636669755000},"page":"311-321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["The IVF-generated human embryonic microenvironment reverses progestin resistance in endometrial cancer cells by inducing cancer stem cell differentiation"],"prefix":"10.1016","volume":"526","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6010-7331","authenticated-orcid":false,"given":"Di","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuoshu","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qimeng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiqing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingzhu","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenbo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2021.11.003_bib1","first-page":"225","article-title":"Cancer statistics, 2009","volume":"59","author":"Jemal","year":"2009","journal-title":"Ca - Cancer J. Clin."},{"key":"10.1016\/j.canlet.2021.11.003_bib2","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/ijgc-00009577-200409000-00028","article-title":"High-risk endometrial cancer in young indigent women","volume":"14","author":"Ben-Arie","year":"2004","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.canlet.2021.11.003_bib3","doi-asserted-by":"crossref","first-page":"358 e1","DOI":"10.1016\/j.ajog.2013.06.031","article-title":"Combined medroxyprogesterone acetate\/levonorgestrel-intrauterine system treatment in young women with early-stage endometrial cancer","volume":"209","author":"Kim","year":"2013","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.canlet.2021.11.003_bib4","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(16)30152-8","article-title":"Combined modality adjuvant therapy for high-risk endometrial cancer","volume":"17","author":"Vanderstichele","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2021.11.003_bib5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdv484","article-title":"ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up","volume":"27","author":"Colombo","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2021.11.003_bib6","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1586\/14737140.4.4.679","article-title":"Current treatment options for endometrial cancer","volume":"4","author":"Santin","year":"2004","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.canlet.2021.11.003_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040602","article-title":"The perspectives of fertility preservation in women with endometrial cancer","volume":"13","author":"Knez","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2021.11.003_bib8","doi-asserted-by":"crossref","first-page":"669 e1","DOI":"10.1016\/j.ajog.2017.08.007","article-title":"All-cause mortality in young women with endometrial cancer receiving progesterone therapy","volume":"217","author":"Ruiz","year":"2017","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.canlet.2021.11.003_bib9","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S0090-8258(02)00008-2","article-title":"Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia--precursor of endometrial cancer","volume":"88","author":"Wang","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canlet.2021.11.003_bib10","doi-asserted-by":"crossref","first-page":"5666","DOI":"10.1038\/s41388-018-0360-7","article-title":"Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism","volume":"37","author":"Bai","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2021.11.003_bib11","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/modpathol.2009.25","article-title":"Aberrant survivin expression in endometrial hyperplasia: another mechanism of progestin resistance","volume":"22","author":"Chen","year":"2009","journal-title":"Mod. Pathol. : Off. J. United States Canadian Acad. Pathol. Inc."},{"key":"10.1016\/j.canlet.2021.11.003_bib12","first-page":"1483","article-title":"Mechanism of progestin resistance in endometrial precancer\/cancer through Nrf2-survivin pathway","volume":"9","author":"Fan","year":"2017","journal-title":"Am. J. Tourism Res."},{"key":"10.1016\/j.canlet.2021.11.003_bib13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/IGC.0b013e318207dac7","article-title":"Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression","volume":"21","author":"Zhang","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.canlet.2021.11.003_bib14","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1111\/j.1447-0756.2012.01881.x","article-title":"Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: in a mouse model","volume":"38","author":"Xu","year":"2012","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"10.1016\/j.canlet.2021.11.003_bib15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0304-3835(92)90180-4","article-title":"Apparent resistance in human endometrial carcinoma during combination treatment with tamoxifen and progestin may result from desensitization following downregulation of tumor progesterone receptor","volume":"62","author":"Satyaswaroop","year":"1992","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2021.11.003_bib16","first-page":"4190","article-title":"Consequences of loss of progesterone receptor expression in development of invasive endometrial cancer","volume":"9","author":"Hanekamp","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2021.11.003_bib17","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/0002-9378(90)91293-L","article-title":"Designing a schedule of progestin administration in the control of endometrial carcinoma growth in the nude mouse model","volume":"162","author":"Mortel","year":"1990","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.canlet.2021.11.003_bib18","doi-asserted-by":"crossref","first-page":"10363","DOI":"10.18632\/oncotarget.7004","article-title":"Mechanism of progestin resistance in endometrial precancer\/cancer through Nrf2-AKR1C1 pathway","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2021.11.003_bib19","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/path.2364","article-title":"Increased expression of the adult stem cell marker Musashi-1 in endometriosis and endometrial carcinoma","volume":"215","author":"Gotte","year":"2008","journal-title":"J. Pathol."},{"key":"10.1016\/j.canlet.2021.11.003_bib20","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1158\/1078-0432.CCR-08-1883","article-title":"Cells with characteristics of cancer stem\/progenitor cells express the CD133 antigen in human endometrial tumors","volume":"15","author":"Rutella","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2021.11.003_bib21","doi-asserted-by":"crossref","first-page":"17739","DOI":"10.1073\/pnas.0503976102","article-title":"Counting human somatic cell replications: methylation mirrors endometrial stem cell divisions","volume":"102","author":"Kim","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2021.11.003_bib22","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1186\/s12885-015-1794-8","article-title":"Stem cell protein Piwil1 endowed endometrial cancer cells with stem-like properties via inducing epithelial-mesenchymal transition","volume":"15","author":"Chen","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2021.11.003_bib23","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.prp.2015.10.008","article-title":"Immunohistochemical expression of cancer stem cell related markers CD44 and CD133 in endometrial cancer","volume":"212","author":"Elbasateeny","year":"2016","journal-title":"Pathol. Res. Pract."},{"key":"10.1016\/j.canlet.2021.11.003_bib24","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1055\/s-0035-1563407","article-title":"Endometrial cancer stem cell as a potential therapeutic target","volume":"33","author":"Kyo","year":"2015","journal-title":"Semin. Reprod. Med."},{"key":"10.1016\/j.canlet.2021.11.003_bib25","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.tranon.2017.07.007","article-title":"Isolation of stem-like cancer cells in primary endometrial cancer using cell surface markers CD133 and CXCR4","volume":"10","author":"Sun","year":"2017","journal-title":"Transl Oncol"},{"key":"10.1016\/j.canlet.2021.11.003_bib26","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/367645a0","article-title":"A cell initiating human acute myeloid leukaemia after transplantation into SCID mice","volume":"367","author":"Lapidot","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.11.003_bib27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.canlet.2012.03.024","article-title":"Targeting a cornerstone of radiation resistance: cancer stem cell","volume":"322","author":"Moncharmont","year":"2012","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2021.11.003_bib28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s12032-014-0069-6","article-title":"Cancer stem cell detection and isolation","volume":"31","author":"Moghbeli","year":"2014","journal-title":"Med. Oncol."},{"key":"10.1016\/j.canlet.2021.11.003_bib29","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1182\/blood-2006-05-024687","article-title":"Characterization of stem cell-like cancer cells in immune-competent mice","volume":"108","author":"Kruger","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2021.11.003_bib30","first-page":"733","article-title":"Stem-like cells in bladder cancer cell lines with differential sensitivity to cisplatin","volume":"32","author":"Falso","year":"2012","journal-title":"Anticancer Res."},{"key":"10.1016\/j.canlet.2021.11.003_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069760","article-title":"Omega-3 eicosapentaenoic acid decreases CD133 colon cancer stem-like cell marker expression while increasing sensitivity to chemotherapy","volume":"8","author":"De Carlo","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2021.11.003_bib32","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s12015-019-09942-y","article-title":"Plasticity of cancer stem cell: origin and role in disease progression and therapy resistance","volume":"16","author":"Das","year":"2020","journal-title":"Stem Cell Rev Rep"},{"key":"10.1016\/j.canlet.2021.11.003_bib33","doi-asserted-by":"crossref","first-page":"8721","DOI":"10.7150\/thno.41648","article-title":"Stem cell programs in cancer initiation, progression, and therapy resistance","volume":"10","author":"Huang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2021.11.003_bib34","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1002\/jcp.26768","article-title":"Ovarian cancer stem cell: a potential therapeutic target for overcoming multidrug resistance","volume":"234","author":"Mihanfar","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.canlet.2021.11.003_bib35","doi-asserted-by":"crossref","first-page":"116781","DOI":"10.1016\/j.lfs.2019.116781","article-title":"Cancer stem cell (CSC) resistance drivers","volume":"234","author":"Najafi","year":"2019","journal-title":"Life Sci."},{"key":"10.1016\/j.canlet.2021.11.003_bib36","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/jb\/mvab021","article-title":"Nanog-mediated stem cell properties is critical for MBNL3 associated paclitaxel resistance of ovarian cancer","volume":"169","author":"Sun","year":"2021","journal-title":"J. Biochem."},{"key":"10.1016\/j.canlet.2021.11.003_bib37","first-page":"2283","article-title":"Endometrial cancer stem cells: a new target for cancer therapy","volume":"32","author":"Kato","year":"2012","journal-title":"Anticancer Res."},{"key":"10.1016\/j.canlet.2021.11.003_bib38","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1073\/pnas.0800467105","article-title":"Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells","volume":"105","author":"Postovit","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2021.11.003_bib39","doi-asserted-by":"crossref","first-page":"5486","DOI":"10.1158\/0008-5472.CAN-10-0713","article-title":"High levels of Nrf2 determine chemoresistance in type II endometrial cancer","volume":"70","author":"Jiang","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2021.11.003_bib40","doi-asserted-by":"crossref","first-page":"108712","DOI":"10.1016\/j.biopha.2019.108712","article-title":"Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression","volume":"113","author":"Jiang","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2021.11.003_bib41","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1158\/0008-5472.CAN-15-1260","article-title":"Infiltrating macrophages induce ERalpha expression through an IL17A-mediated epigenetic mechanism to sensitize endometrial cancer cells to estrogen","volume":"76","author":"Ning","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2021.11.003_bib42","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jim.2009.06.008","article-title":"ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays","volume":"347","author":"Hu","year":"2009","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.canlet.2021.11.003_bib43","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1158\/0008-5472.CAN-08-0364","article-title":"Identification and characterization of ovarian cancer-initiating cells from primary human tumors","volume":"68","author":"Zhang","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2021.11.003_bib44","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1038\/s41467-019-10739-3","article-title":"TSPAN8 promotes cancer cell stemness via activation of sonic Hedgehog signaling","volume":"10","author":"Zhu","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2021.11.003_bib45","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/aogs.13587","article-title":"Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: a systematic review","volume":"98","author":"Travaglino","year":"2019","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"10.1016\/j.canlet.2021.11.003_bib46","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nature11925","article-title":"NANOG-dependent function of TET1 and TET2 in establishment of pluripotency","volume":"495","author":"Costa","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.11.003_bib47","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.stem.2013.02.005","article-title":"Replacement of Oct4 by Tet1 during iPSC induction reveals an important role of DNA methylation and hydroxymethylation in reprogramming","volume":"12","author":"Gao","year":"2013","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.canlet.2021.11.003_bib48","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.drudis.2014.05.002","article-title":"Chemical approaches to targeting drug resistance in cancer stem cells","volume":"19","author":"Sotiropoulou","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.canlet.2021.11.003_bib49","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ygyno.2015.12.022","article-title":"Progestin treatment decreases CD133+ cancer stem cell populations in endometrial cancer","volume":"140","author":"Guy","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canlet.2021.11.003_bib50","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1530\/REP-09-0411","article-title":"A cancer stem cell origin for human endometrial carcinoma?","volume":"140","author":"Hubbard","year":"2010","journal-title":"Reproduction"},{"key":"10.1016\/j.canlet.2021.11.003_bib51","doi-asserted-by":"crossref","first-page":"8241","DOI":"10.1158\/0008-5472.CAN-08-4808","article-title":"Evidence for cancer stem cells in human endometrial carcinoma","volume":"69","author":"Hubbard","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2021.11.003_bib52","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","article-title":"EMT, CSCs, and drug resistance: the mechanistic link and clinical implications","volume":"14","author":"Shibue","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2021.11.003_bib53","first-page":"3714190","article-title":"Cancer stem cells and their microenvironment: biology and therapeutic implications","author":"Lau","year":"2017","journal-title":"Stem cells Int."},{"key":"10.1016\/j.canlet.2021.11.003_bib54","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1158\/0008-5472.CAN-18-1234","article-title":"p53-Suppressed oncogene TET1 prevents cellular aging in lung cancer","volume":"79","author":"Filipczak","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2021.11.003_bib55","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/1940-6207.CAPR-14-0306","article-title":"Aberrant TET1 methylation closely associated with CpG island methylator phenotype in colorectal cancer","volume":"8","author":"Ichimura","year":"2015","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.canlet.2021.11.003_bib56","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1158\/0008-5472.CAN-15-1910","article-title":"Loss of Tet1-associated 5-hydroxymethylcytosine is concomitant with aberrant promoter hypermethylation in liver cancer","volume":"76","author":"Thomson","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2021.11.003_bib57","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/00365521.2016.1253767","article-title":"Association of TET1 expression with colorectal cancer progression","volume":"52","author":"Tian","year":"2017","journal-title":"Scand. J. Gastroenterol."},{"key":"10.1016\/j.canlet.2021.11.003_bib58","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.stem.2011.01.008","article-title":"Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells","volume":"8","author":"Koh","year":"2011","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.canlet.2021.11.003_bib59","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.placenta.2017.09.008","article-title":"Dynamic expression of TET1, TET2, and TET3 dioxygenases in mouse and human placentas throughout gestation","volume":"59","author":"Rakoczy","year":"2017","journal-title":"Placenta"},{"key":"10.1016\/j.canlet.2021.11.003_bib60","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.stem.2011.07.010","article-title":"Tet1 is dispensable for maintaining pluripotency and its loss is compatible with embryonic and postnatal development","volume":"9","author":"Dawlaty","year":"2011","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.canlet.2021.11.003_bib61","doi-asserted-by":"crossref","first-page":"E4236","DOI":"10.1073\/pnas.1510510112","article-title":"Simultaneous deletion of the methylcytosine oxidases Tet1 and Tet3 increases transcriptome variability in early embryogenesis","volume":"112","author":"Kang","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2021.11.003_bib62","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/nature12805","article-title":"Role of Tet1 in erasure of genomic imprinting","volume":"504","author":"Yamaguchi","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.11.003_bib63","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4161\/cbt.27144","article-title":"5-hydroxymethylcytosine: a new insight into epigenetics in cancer","volume":"15","author":"Ye","year":"2014","journal-title":"Cancer Biol. Ther."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521005693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521005693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:02:51Z","timestamp":1759593771000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383521005693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":63,"alternative-id":["S0304383521005693"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2021.11.003","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The IVF-generated human embryonic microenvironment reverses progestin resistance in endometrial cancer cells by inducing cancer stem cell differentiation","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2021.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}